Corticobasal syndrome

CBS is the most common type of corticobasal degeneration (CBD) although the terms CBD and CBS have been used interchangeably in the past. ==Symptoms and signs==

Symptoms of CBS include apraxia, alien limb phenomenon, frontal deficits, and extrapyramidal motor symptoms such as myoclonus or rigidity. Movement deficits often begin on one side and progress to the other. ==Pathophysiology==

CBD is the pathology underlying approximately 50% of CBS cases. ==Diagnosis==

The Armstrong criteria were proposed in 2013; the accuracy of these is limited and further research is needed. Symptoms may be symmetric or asymmetric, with one or more of the following: • limb rigidity or akinesia • limb dystonia • limb myoclonus, plus one of: • orobuccal or limb apraxia • cortical sensory deficit • alien limb phenomena (more than simple levitation) The onset is insidious with gradual progression, lasting one year or more, with no exclusion criteria present. The diagnosis is more likely if onset is after age 50, there is no family history (2 or more relatives), and there is no genetic mutation affecting T (e.g., MAPT). The diagnostic criteria for clinical use may result in a misdiagnosis of other tau-based diseases. The symptoms of classic CBS differ from CBD in that CBD also includes cognitive deficits in the executive functions. ==Prognosis==

The average survival time after disease onset is estimated at 6.5 years. ==References==